Nama's AI scorecard currently rates STAAR Surgical Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is STAA's P/E ratio?

STAAR Surgical trades at a trailing price-to-earnings ratio of 34.1.

When does STAA report earnings?

STAAR Surgical's next scheduled report is on Mar 2, 2027. Analysts expect EPS of $0.09.

What is the STAA price target?

The median analyst price target from 9 analysts is $27.00, with a range of $19.00 – $37.00.

Is STAA Shariah compliant?

Nama's AAOIFI-style screen reads STAAR Surgical as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

STAAR Surgical (STAA)

Healthcare · Medical Instruments Supplies · NASDAQ

STAAR Surgical (STAA) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $1.27B, a trailing price-to-earnings ratio of 34.1 and a free-cash-flow yield of -3.2%. Over the most recent reported fiscal year, revenue declined 23.7%. Nama's AI scorecard rates it Hold, 5.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.2/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -16.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-79.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.27B
Trailing P/E	34.1
Price / book	3.5
Price / sales	3.7
FCF yield	-3.2%
Dividend yield	—
Gross margin	76.6%
Operating margin	12.1%
Net margin	1.1%
Revenue growth (YoY)	-23.7%
Revenue growth (3-yr annual)	-5.6%
EPS growth (YoY)	-409.5%
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

STAA earnings

Next report: Mar 2, 2027 (Q4 2026, EPS estimate $0.09). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.19	$0.17	+11.8%	$83.41M
Q2 2026	Aug 12, 2026	$0.25	$0.23	+8.7%	$93.53M
Q1 2026	May 13, 2026	$0.29	$0.08	+262.5%	$93.52M
Q4 2025	Mar 3, 2026	$0.01	$0.17	-94.1%	$57.80M

STAA analyst price target

Median target $27.00 from 9 analysts, ranging $19.00 – $37.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live STAA data on Nama Insights →

STAA FAQ

Is STAA a buy?: Nama's AI scorecard currently rates STAAR Surgical Hold (5.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is STAA's P/E ratio?: STAAR Surgical trades at a trailing price-to-earnings ratio of 34.1.
When does STAA report earnings?: STAAR Surgical's next scheduled report is on Mar 2, 2027. Analysts expect EPS of $0.09.
What is the STAA price target?: The median analyst price target from 9 analysts is $27.00, with a range of $19.00 – $37.00.
Is STAA Shariah compliant?: Nama's AAOIFI-style screen reads STAAR Surgical as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.